Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05570955 · ClinicalTrials.gov registry record · NA

Deucravacitinib Adherence Study

A NA study of Psoriasis, sponsored by Wake Forest University Health Sciences.

Active
Registry status
NA
Development phase
40
Enrollment target
1
Study location

NCT05570955: Active NA study of Psoriasis, sponsored by Wake Forest University Health Sciences.

NCT05570955 is a NA study of Psoriasis that is active but no longer recruiting, run by Wake Forest University Health Sciences. The registered enrollment target is 40 participants, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05570955, a NA study of Psoriasis, is active but no longer recruiting, sponsored by Wake Forest University Health Sciences.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

Psoriasis patients are very poorly adherent to topical treatment. If adherence issues are ignored, poor adherence may limit the real-world efficacy of deucravacitinib, too. Forty psoriasis patients recruited from Wake Forest Baptist Health Dermatology Clinic will be enrolled. Twenty will be randomized to a reporting intervention designed to promote better adherence and the remaining 20 patients will serve as controls who will not receive a reporting intervention. Through qualitative interviews of the 40 patients recruited, we plan to study the behaviors of the most adherent patients to better understand specific beliefs and behaviors of adherent patients and to identify practical, modifiable factors that can improve adherence. We will also compare treatment outcomes and efficacy of deucravacitinib between the most and least adherence patients.

Primary Outcome

Qualitative data will be obtained from detailed, systematic interviews at 3-month follow-up to Adherence to treatment will be captured using electronic monitors that record the timing of medication dosing events and the number of pills taken at each event (based on weight of medication using Sensal Health adherence monitoring device) measured at 3 month close-out visit

Conditions Studied

Interventions

  • BEHAVIORAL Text reminder

Study Locations (1)

North Carolina

  • Wake Forest University Health Sciences Department of Dermatology - Winston-Salem

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2023-07-24
Est. Completion 2026-08
Phase NA
Wake Forest University Health Sciences

1,140 total trials

What the registry record for NCT05570955 still lists

NCT05570955 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (92% lower).

The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 1 intervention - of which Text reminder is the first listed.

NCT05570955 reports a single indexed study location in North Carolina.

Frequently Asked Questions

What is clinical trial NCT05570955 about?

NCT05570955 is a clinical study titled "Deucravacitinib Adherence Study". Psoriasis patients are very poorly adherent to topical treatment. If adherence issues are ignored, poor adherence may limit the real-world efficacy of deucravacitinib, too. Forty psoriasis patients recruited from Wake Forest Baptist Health Dermatology Clinic will be enrolled. Twenty will be randomiz...

What is the current status of trial NCT05570955?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2023-07-24. Estimated completion is 2026-08.

What conditions does trial NCT05570955 study?

This clinical trial studies the following conditions: Psoriasis.

What interventions are being tested in trial NCT05570955?

The interventions under investigation include: Text reminder (BEHAVIORAL).

Who is sponsoring clinical trial NCT05570955?

This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05570955 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Psoriasis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05570955's enrollment target sits among peer trials

40 83rd of 125 higher than 40 of 125 other Psoriasis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Psoriasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05570955, the US trial registry maintained by the National Library of Medicine. NCT05570955 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.